News
HanchorBio Outlines Global Strategy for Gastric Cancer Immunotherapy as HCB101 Advances Beyond Phase 1
HanchorBio announced that Alvin Luk, PhD, MBA, CCRA, President and Chief Medical Officer (Group) and CEO (USA) of HanchorBio, presented the Company’s vision for the next phase of gastric cancer immunotherapy at the Early Phase Clinical Trials: Innovation and Precision Medicine Forum in Taichung, Taiwan.
Aug 24, 2026
Read more
HanchorBio Advances Myeloid-Directed Therapeutics Strategy Beyond Oncology with HCB101 Clinical Progress and FBDB™ Platform Expansion
HanchorBio shared its latest clinical and research progress in myeloid-directed therapeutics at the 2026 Autumn Industry Trends and Corporate Forum hosted by Hua Nan Securities.
The Company presented its development strategy centered on the proprietary FBDB™ multifunctional biologics platform and myeloid enhancer approach, highlighting clinical progress of HCB101 in solid tumors and the expansion of macrophage-directed biology into HCB206 for immune-mediated diseases.
Aug 21, 2026
Read more
HanchorBio Announces HCB301 Oral Presentation and HCB101 Best Poster Selection at KSMO 2026
HanchorBio announced that three abstracts featuring its clinical-stage programs HCB101 and HCB301 have been accepted for presentation at KSMO 2026—the 19th Annual Meeting of the Korean Society of Medical Oncology and 2026 International Conference—held in conjunction with the 14th International Conference of the Federation of Asian Clinical Oncology (FACO), taking place September 2–4, 2026, in Seoul, Korea.
Aug 19, 2026
Read more
From Macrophage Biology to Clinical Development: HanchorBio Advances the Future of Gastric Cancer Immunotherapy
HanchorBio announced insights from the “Taiwan Gastric Cancer Experts Forum on Clinical Challenges and Emerging Immunotherapy”, held August 8–9 in Taichung, Taiwan.
Aug 10, 2026
Read more
HanchorBio and Taiwan Cancer Moonshot Team Led by Professor Sung-Liang Yu Establish Strategic Collaboration to Advance Precision Oncology
HanchorBio announced that its wholly owned Taiwan subsidiary has entered into a strategic collaboration with the research team led by Professor Sung-Liang Yu of National Taiwan University, a key participating team in the Taiwan Cancer Moonshot Program (TCMP). The collaboration has been formalized through a memorandum of understanding signed by HanchorBio Taiwan and Professor Yu’s team.
Aug 07, 2026
Read more
HanchorBio Invited to Present at the 9th BPD Biopharmaceutical Process Development Conference on Next-Generation Drug Manufacturing and CMC Development
HanchorBio announced that Vivian Kuo, PhD, Executive Director of CMC, has been invited to speak at the 2026 9th BPD Biopharmaceutical Process Development Conference.
Aug 05, 2026
Read more
HanchorBio Brings Clinical Anchor-to-Platform Strategy to BIO Asia–Taiwan 2026
HanchorBio announced that it will present its clinical development and platform strategy at BIO Asia–Taiwan 2026, taking place July 16–19, 2026, in Taipei, Taiwan.
Jul 13, 2026
Read more
HanchorBio Presents Two Oral Presentations at ESMO TAT Asia 2026 Highlighting Progress Across Its Next-Generation Immunotherapy Pipeline
HanchorBio announced that two company-sponsored clinical programs were featured in oral presentations at the European Society for Medical Oncology Targeted Anticancer Therapies Asia Congress 2026, ESMO TAT Asia 2026, held in Hong Kong.
Jun 13, 2026
Read more
HanchorBio Presents Late-Breaking Data at FOCIS 2026 Supporting Innate-Immune Product Engine Across Oncology and Autoimmune Disease
HanchorBio announced the presentation of late-breaking clinical and translational data at the Federation of Clinical Immunology Societies Annual Meeting, FOCIS 2026, being held June 9-12, 2026, in San Francisco.
Jun 10, 2026
Read more
HanchorBio Presents Two ASCO 2026 Abstracts Highlighting HCB101 Combination Activity and HCB301 First-in-Human Clinical Progress
HanchorBio announced updated clinical data for HCB101 and HCB301 presented at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
Jun 01, 2026
Read more